NeuroSigma Inks Exclusive License with UCLA for TFN Stent Technology

NeuroSigma Inc. (Los Angeles, CA, USA), a medical technology company, signed an exclusive license agreement with the University of California at Los Angeles (UCLA; USA), for its medical applications of Thin-Film Nitinol (TFN) technology, forming a majority owned subsidiary, NSVascular Inc. The new subsidiary will develop and commercialize TFN-covered stents for endovascular applications made of the superelastic nickel and titanium alloy, Nitinol.

A multidisciplinary team including researchers from the UCLA Henry Samueli School of Engineering and Applied Science and doctors from the David Geffen School of Medicine at UCLA has collaborated in the development and in vitro/in vivo testing of the first two applications of TFN-covered stents. These novel applications are flow-diverting stents for intracranial aneurysms (IA) and for treating peripheral artery disease (PAD).

"For the past five years our engineering team has benefited from collaborating with a top-notch UCLA medical team, spearheaded by Dr. Dan Levi and Dr. Fernando Vinuela. I am looking forward to working closely with the experienced management team at NeuroSigma and NSVascular in commercializing this promising technology," said Greg Carman, PhD, UCLA professor of mechanical and aerospace engineering and a cofounder of NSVascular.

"We are very excited that NSVascular will be moving this technology through translational studies and hopefully ultimately to patients thereby benefiting both society and the economy at large," said Earl Weinstein, associate director of UCLA's Office of Intellectual Property.

"We are delighted to have signed our fourth license with UCLA's Office of Intellectual Property and look forward to working closely with a new team of engineers and physicians from UCLA," said Lodwrick M. Cook, chairman of NeuroSigma.

Related Links:
NeuroSigma
UCLA